Globally, obesity and type 2 diabetes mellitus (T2DM) have reached epidemic proportions. According to recent WHO data, one in eight people worldwide was living with obesity in 2022, and nearly half of all adults (43%) are overweight.¹ Concurrently, the prevalence of diabetes has surged: by 2022 an estimated 830 million people had diabetes worldwide.² Obesity and T2DM are tightly linked through complex metabolic and inflammatory pathways. Expanded adipose tissue in obesity secretes dysregulated adipokines and cytokines, leading to chronic low-grade inflammation. Adipocyte hypertrophy and hypoxia provoke macrophage infiltration into adipose tissue and release of factors such as pro-inflammatory cytokines. These pro-inflammatory signals impair insulin receptor signaling in muscle and liver, reducing glucose uptake and increasing hepatic gluconeogenesis, while also promoting pancreatic β-cell dysfunction (1).

Bariatric surgery has emerged as the most effective treatment for severe obesity, consistently producing greater and more durable weight loss than non-surgical interventions. In addition to weight loss, bariatric procedures confer profound metabolic benefits. Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) in particular achieve sustained weight reduction beyond 10 years while dramatically improving obesity-related comorbidities (2). These weight-independent effects implicate altered gut physiology as key mechanisms. Postoperatively, patients typically show exaggerated postprandial incretin responses: elevations in glucagon-like peptide-1 (GLP-1) and peptide YY (PYY) that enhance insulin secretion and satiety (3, 4). RYGB, by bypassing the proximal intestine, acutely delivers nutrients to the distal gut and evokes strong GLP-1 and bile acid signals, whereas SG reduces ghrelin (a hunger hormone) and similarly boosts GLP-1/PYY responses (5). In parallel, adipose-derived inflammation is attenuated after surgery (6).

Despite clear overall benefits, debate persists regarding which bariatric procedure optimally treats T2DM. Observational and trial evidence often favors RYGB for glycemic remission. For example, in a pooled analysis of randomized trials, RYGB produced a higher diabetes remission rate than SG at 1 year (7). However, differences tend to attenuate over time: in studies with 2–5-year follow-up, remission rates with SG approached those of RYGB (5, 7). Adjustable gastric banding (AGB) is generally less effective. Comparative data show much lower remission rates after AGB than after RYGB or SG (8). For instance, a landmark U. K. cohort found 2-year remission in only ~7% of AGB patients versus ~41% after RYGB and 26% after SG (8). Biliopancreatic diversion (BPD) or duodenal switch, a more complex procedure, yields the highest remission (often >90%) (8). A recent study of insulin-treated patients confirmed that BPD-DS conferred superior long-term remission compared to other procedures (9). The literature contains some conflicting signals: some reviews assert RYGB’s superiority, while others find only transient differences (5, 7). Variability among patients (age, diabetes duration, baseline β-cell function, etc.) also affects outcomes. For example, the one study found that patients with lower preoperative hemoglobin A1c (HbA1c) and fewer diabetes medications were far more likely to maintain remission at 10 years (10).

Given these gaps, a comprehensive synthesis of the most recent evidence is needed. Our systematic review and meta-analysis evaluates all major bariatric procedures (RYGB, SG, AGB, and BPD) and their effects on a wide range of glycemic (HbA1c, fasting blood glucose (FBG), postprandial glucose (PPG)) and metabolic markers (fasting insulin, homeostatic model assessment of insulin resistance (HOMA-IR), C-peptide) in people with T2DM. This broad comparison offers a more complete picture of their relative efficacy. Importantly, we formally assess the certainty of the evidence using GRADE methodology to provide clinicians with clearer guidance.

This study was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (11). It was registered in PROSPERO with an ID: CRD420251063420.

The findings from this meta-analysis underscore the profound impact of bariatric surgery on improving glycemic and metabolic outcomes in obese individuals with T2DM. Despite the overall improvements in glycemic parameters, the effect of bariatric surgery on HbA1c levels was not statistically significant in the primary analysis. This finding may reflect the complex interplay of factors influencing long-term glycemic control, including patient adherence, variability in surgical procedures, and baseline glycemic status. Notably, the GRADE quality for HbA1c was rated as low, indicating limited confidence in the reliability of this outcome. This suggests that future high-quality, long-term RCTs are needed to better clarify the true effect of bariatric surgery on HbA1c. Interestingly, after performing the trim and fill analysis to account for potential publication bias, the effect on HbA1c became statistically significant, highlighting how methodological limitations and potential reporting biases may obscure true effects. Significant reductions were observed in FBG, PPG, and HOMA-IR, along with modest improvements in C-peptide and fasting insulin levels. Evidence on FBG, PPG, C-peptide levels, HOMA-IR, and fasting insulin levels had high GRADE quality. These results align with the growing body of evidence demonstrating that bariatric surgery offers not only weight loss but also effective glycemic control and metabolic regulation, often resulting in partial or complete diabetes remission.

Multiple meta-analyses of RCTs have shown dramatic improvements in glycemic control and diabetes remission with bariatric surgery. For example, Wu et al. pooled 8 RCTs and found bariatric surgery gave a ~ 5.8-fold higher remission rate and much larger drops in HbA1c and fasting glucose than medical therapy (57). Kim et al. similarly reported T2DM remission rates of ~47% after RYGB, 42% after sleeve, and 25% after banding, versus only ~5% with medical care; mean HbA1c fell by ~0.96–0.97% after RYGB/SG but not with medical treatment (58). Meta-analyses comparing surgical procedures found RYGB tends to induce higher short-term remission than SG. Borgeraas et al. analyzed 10 RCTs and observed 1-year remission of 57% after RYGB vs. 47% after SG (RR ≈ 1.20), though by 2–5 years the rates were similar (7). Large pooled analyses (n ≈ 22,000) have also reported ~83.8% diabetes resolution after RYGB vs. ~ 47.8% after gastric banding (59). Overall, prior work consistently showed that more aggressive procedures (RYGB, BPD) yielded higher remission and glycemic improvements than restrictive ones. Few meta-reviews focused on insulin/HOMA. Rao et al. (2012) documented dramatic insulin-sensitivity gains after surgery – e.g. HOMA-IR fell by ~40–60% or more by 6–12 months, with particularly rapid drops after RYGB and BPD (60). However, most earlier meta-analyses did not report insulin, C-peptide, or HOMA-IR changes. These earlier analyses generally pooled relatively small numbers of trials and focused on a limited set of outcomes (mostly weight, HbA1c, fasting glucose, and remission). Many did not stratify results by procedure type or include newer RCTs, and none had fully comprehensive quality/GRADE appraisals of the evidence.

The significant reduction in FBG levels, as highlighted by the pooled WMD of −0.82 mg/dL, was consistent with previous studies, further emphasizing the effectiveness of surgical intervention over conventional medical management (61). The high heterogeneity observed in this analysis is consistent with variability in baseline characteristics, surgical techniques, and follow-up durations among the included studies. Following the trim-and-fill analysis, the pooled estimate for HbA1c demonstrated a WMD of −3.99%, confirming a substantial and clinically meaningful impact of bariatric surgery on long-term glycemic control compared to non-surgical interventions. This adjusted estimate suggests that the initial non-significant findings may have been influenced by publication bias. Our results align with prior long-term studies reporting sustained reductions in HbA1c levels up to 5 years postoperatively in patients undergoing bariatric surgery (61). While heterogeneity remains a concern, likely due to differences in patient populations and pre-surgical glycemic status, the findings strongly support the role of bariatric surgery as a metabolic intervention for diabetes management. The results for PPG reduction were consistent with prior studies that demonstrated improved incretin responses post-surgery, which contributes to better PPG control (62). The modest improvement in C-peptide levels, reflected by the pooled WMD of 0.38 ng/mL, suggests partial restoration of beta-cell function following bariatric surgery. This finding corroborates earlier research indicating that bariatric surgery improves pancreatic function and preserves residual beta-cell activity (63). However, the variability in results across studies points to heterogeneity in baseline beta-cell function and the degree of insulin resistance among patients. The significant reduction in HOMA-IR levels, with pooled WMD of −2.81, highlights the role of bariatric surgery in reducing insulin resistance, a hallmark of T2DM. Prior studies have consistently demonstrated that weight loss and improved adipokine profiles post-surgery contribute to enhanced insulin sensitivity (63). Lastly, the improvement in fasting insulin levels (pooled WMD of −0.62 μU/mL) aligns with prior evidence indicating that bariatric surgery reduces compensatory hyperinsulinemia. This outcome is likely driven by a combination of reduced insulin resistance and improved glucose metabolism post-surgery (64). The variability observed in the magnitude of fasting insulin changes across studies may reflect differences in baseline insulin levels, surgical methods, and follow-up durations. Overall, the results strongly support bariatric surgery as an effective intervention for improving glycemic control and metabolic outcomes in obese patients with T2DM.

The observed reductions in fasting blood glucose, postprandial glucose, and HbA1c levels post-bariatric surgery can be attributed to several physiological mechanisms (65). One of the most significant is the improvement in insulin sensitivity due to weight loss and changes in adipokine secretion. Bariatric surgery reduces visceral adiposity, which is strongly associated with insulin resistance, and leads to decreased secretion of pro-inflammatory cytokines like tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6). These changes reduce systemic inflammation and improve insulin signaling (66). Additionally, the alterations in gut hormone dynamics play a critical role. Increased levels of GLP-1 following surgery enhance glucose dependent insulin secretion, suppress glucagon release, and slow gastric emptying, all of which contribute to better glycemic control (67). The improvement in C-peptide levels and reductions in HOMA-IR suggest partial restoration of beta-cell function and reduced insulin resistance (68). The “foregut hypothesis” proposes that exclusion of the proximal small intestine enhances insulin sensitivity, while the “hindgut hypothesis” highlights the role of accelerated nutrient delivery to the distal intestine in stimulating GLP-1 secretion. Furthermore, bariatric surgery leads to a reduction in hepatic glucose output, likely through decreased lipotoxicity and improved liver insulin sensitivity. These metabolic changes collectively contribute to the observed reductions in fasting insulin levels and better overall glycemic control (69).

This meta-analysis is comprehensive, synthesizing data from 39 studies with a large sample size of participants, which enhances the robustness of the findings. The inclusion of multiple glycemic and metabolic outcomes provides a nuanced understanding of the impact of bariatric surgery on T2DM. Rigorous statistical methods, including sensitivity analyses and assessments of publication bias, lend credibility to the results. The adherence to PRISMA guidelines ensures transparency and reproducibility, making the findings reliable for clinical and research purposes. Despite its strengths, this review has several limitations. It is important to acknowledge that many included studies were rated as having a high risk of bias, primarily due to variability in laboratory follow-up protocols and inconsistent reporting standards. These factors may reduce the overall confidence in the pooled results and should be considered when interpreting the findings. The substantial heterogeneity observed across studies for outcomes like FBG, and PPG levels limits the generalizability of the findings. The included studies exhibited considerable variability in sample sizes and follow-up durations, ranging from as few as 6 to nearly 480 participants and from just over 2 months to 10 years. Such heterogeneity may influence the precision and generalizability of the pooled estimates. Smaller studies are more prone to random error, and shorter follow-up periods may not capture the durability of metabolic improvements, particularly for longer-term markers like HbA1c. This variation highlights the need for more standardized, long-term trials with adequate sample sizes to confirm and extend these findings. Additionally, the lack of uniform reporting on comorbid conditions and medication use makes it challenging to isolate the effects of bariatric surgery. Finally, factors such as the presence of cardiovascular disease, hypertension, or dyslipidemia, as well as the type and duration of antidiabetic medication use can significantly affect metabolic outcomes and glycemic response following bariatric surgery. Due to inconsistent or missing data, we were unable to perform adjusted analyses or stratify results based on these clinical variables. Future studies should prioritize standardized reporting of comorbidity profiles and medication regimens to allow for more precise assessments of surgical efficacy and its interaction with medical management.

The findings of this meta-analysis have significant implications for clinical practice. Bariatric surgery should be considered a key therapeutic option for obese patients with T2DM, particularly those with poor glycemic control despite optimal medical therapy. The observed reductions in fasting blood glucose, and postprandial blood glucose levels suggest that surgery can achieve better glycemic outcomes compared to conventional treatments. These benefits are likely to translate into reduced risks of diabetes-related complications, such as retinopathy, nephropathy, and cardiovascular disease. Additionally, the improvements in insulin sensitivity and beta-cell function may delay or prevent disease progression, further enhancing patient quality of life. Clinicians should weigh the risks and benefits of surgery and provide individualized recommendations based on patient preferences, comorbidities, and surgical eligibility criteria.

Future research should focus on understanding the long-term durability of glycemic and metabolic improvements following bariatric surgery. Studies with extended follow-up durations are needed to assess the sustainability of outcomes such as HbA1c and HOMA-IR reductions. Randomized controlled trials comparing different bariatric procedures in diverse populations could provide valuable insights into procedure-specific effects. Additionally, research should explore the role of genetic and epigenetic factors in modulating responses to surgery. Mechanistic studies investigating changes in gut microbiota and their relationship with glycemic outcomes could shed light on novel pathways of metabolic regulation. Finally, economic evaluations assessing cost-effectiveness in different healthcare settings could guide policy decisions.

This meta-analysis demonstrates that bariatric surgery significantly improves glycemic and metabolic outcomes in obese individuals with T2DM. The substantial reductions in FBG, and PPG, coupled with improvements in insulin sensitivity and beta-cell function, highlight the metabolic benefits of surgical intervention beyond weight loss. These findings underscore the need for greater integration of bariatric surgery into diabetes care pathways, offering hope for better disease management and improved patient outcomes.